GUANGZHOU, China, May 18, 2026 /PRNewswire/ -- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord BioPharma, Inc, the U.S. specialty division of Intas Pharmac… For the full story, visit the source.
Science
Bio-Thera Solutions' Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States
GUANGZHOU, China, May 18, 2026 /PRNewswire/ -- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord BioPharma, Inc, the U.S. specialty division of Intas Pharmac…
PRNewswire· 5 months ago· 2 min read
This summary is sourced from PRNewswire. Read the full article at:PRNewswire